✦ Free PDF Download of Your Custom Analysis With Actionable Solutions After Token Purchase ✦
Token-based platform — single use from $1.99 · Pro packages available
SAMPLE ONLY
Prior Authorization — Tremfya (Guselkumab) · Plaque Psoriasis · UnitedHealthcare · FL
PRISM® ANALYSIS REPORT · PA VARIANT · SAMPLE OUTPUT · March 2026
A prior authorization request for guselkumab (Tremfya) 100mg subcutaneous injection was submitted to UnitedHealthcare for a 38-year-old patient with moderate-to-severe plaque psoriasis (ICD-10: L40.0) covering approximately 15% body surface area (BSA), with PASI score of 18 and documented significant impact on quality of life. The patient has documented failure of two conventional systemic agents — methotrexate (hepatotoxicity, discontinued after 4 months) and apremilast (Otezla, inadequate response after 6 months, BSA improvement less than 25%).
UHC requires biologic step therapy for psoriasis: conventional systemic agents must be tried and documented as failed before an IL-23 inhibitor like Tremfya will be approved. The most likely denial risk is that UHC's formulary may additionally require a TNF inhibitor trial (adalimumab/Humira or etanercept) before an IL-23 inhibitor is approved, depending on the specific plan. This package maps each criterion and flags this critical verification step.
SAMPLE LETTER — LETTER OF MEDICAL NECESSITY
[PRACTICE LETTERHEAD]
[DATE]
To: UnitedHealthcare Prior Authorization Department
Re: Prior Authorization Request — Guselkumab (Tremfya) 100mg Subcutaneous Injection
HCPCS: J0224 (or applicable J-code — verify with UHC at time of submission)
Patient: [REQUIRED: Patient full name]
Date of Birth: [REQUIRED]
Member ID: [REQUIRED: UHC member ID]
Group Number: [REQUIRED]
Dear Prior Authorization Medical Director,
I am writing to request prior authorization for guselkumab (Tremfya) 100mg subcutaneous injection for a 38-year-old patient with moderate-to-severe plaque psoriasis (ICD-10: L40.0). This request is medically necessary. The patient has documented failure of two conventional systemic agents at adequate doses and durations, and presents with disease severity that is not compatible with quality of life or adequate disease control on available conventional therapies.
DISEASE SEVERITY AND CLINICAL PRESENTATION
Diagnosis: Moderate-to-severe plaque psoriasis (L40.0)
Body Surface Area (BSA): 15% — moderate-to-severe threshold confirmed (BSA ≥10%)
PASI Score: 18 — moderate-to-severe (PASI ≥12)
DLQI Score: [REQUIRED: Dermatology Life Quality Index — document in office note; score ≥10 indicates very large effect on quality of life]
Disease distribution: [REQUIRED: describe location — trunk, extremities, scalp, hands/feet, nails]
Duration of disease: [REQUIRED: years]
Psoriatic arthritis: [REQUIRED: confirm presence or absence — affects formulary considerations]
CONVENTIONAL SYSTEMIC THERAPY FAILURE
Agent 1: Methotrexate
▸ Dose: [REQUIRED: e.g., 15–25mg weekly oral or subcutaneous]
â–¸ Duration: 4 months
▸ Outcome: Discontinued due to hepatotoxicity — elevated LFTs documented
â–¸ Documentation: [REQUIRED: lab report showing LFT elevation; chart note documenting clinical decision to discontinue]
▸ Failure basis: Adverse effect / safety — unable to continue
Agent 2: Apremilast (Otezla)
â–¸ Dose: 30mg BID (standard maintenance dose)
â–¸ Duration: 6 months
▸ Outcome: Inadequate therapeutic response — BSA improvement less than 25% at end of trial period
â–¸ Documentation: [REQUIRED: sequential BSA measurements or PASI scores showing less than 25% improvement; office notes from start and end of trial]
▸ Failure basis: Inadequate efficacy — failed to achieve meaningful disease control
MEDICAL NECESSITY FOR GUSELKUMAB (TREMFYA)
Guselkumab is an IL-23 inhibitor (anti-p19 monoclonal antibody) with FDA approval for moderate-to-severe plaque psoriasis. It selectively targets IL-23, a key cytokine in psoriasis pathogenesis, producing durable skin clearance with a favorable safety profile. In the VOYAGE 1 and VOYAGE 2 trials, guselkumab achieved PASI 90 response in approximately 73% of patients at week 16 — representing a substantially higher response rate than conventional agents and comparable or superior efficacy to other biologics in this class.
This patient has failed two conventional systemic agents across two different mechanisms of action (antimetabolite and PDE4 inhibitor). The residual disease burden — BSA 15%, PASI 18 — represents ongoing moderate-to-severe disease despite adequate systemic therapy trials. Guselkumab is the evidence-based, guideline-concordant next-line biologic intervention for this patient's disease profile.
[REQUIRED: If UHC requires TNF inhibitor step — add clinical rationale for why TNF inhibitor step should be waived, or document TNF inhibitor trial if one was completed]
Sincerely,
[REQUIRED: Dermatologist full name, credentials, NPI, practice, signature]
RECOMMENDED DOCUMENTATION CHECKLIST
BSA and PASI scores documented in most recent office note — both required for moderate-to-severe threshold
→ BSA ≥10% OR PASI ≥12 establishes moderate-to-severe disease. Document both in the office note closest to PA submission. Sequential measurements showing persistent disease severity strengthen the case.
REQUIRED
DLQI (Dermatology Life Quality Index) score documented
→ DLQI ≥10 indicates very large effect on quality of life and is increasingly required by UHC for biologic PA. If not already documented, administer and score at the next visit before submission.
REQUIRED
Lab report showing LFT elevation during methotrexate trial
→ Must show: patient name, collection date, LFT values (ALT, AST) above normal range, during or immediately after the methotrexate trial period. This is the objective evidence of hepatotoxicity — without it, the methotrexate failure is narrative only.
REQUIRED
Sequential BSA or PASI measurements showing less than 25% improvement on apremilast
→ Document BSA/PASI at apremilast initiation AND at the end of the 6-month trial. Less than 25% improvement from baseline is the standard inadequate response threshold. Side-by-side measurements in office notes or a treatment log are ideal.
REQUIRED
Verify whether UHC plan requires TNF inhibitor trial before IL-23 inhibitor
→ CRITICAL: Call UHC Provider Services before submitting: "Does your current clinical policy bulletin for guselkumab (Tremfya) require a TNF inhibitor trial (adalimumab, etanercept) before an IL-23 inhibitor for this patient's plan?" Some UHC plans require this step — it is the single highest-risk unknown in this submission.
REQUIRED
Tuberculosis (TB) screening — negative PPD or IGRA required before biologic initiation
→ UHC requires documented negative TB screening before approving any biologic. TB test must be current (typically within 12 months). If TB screening is positive, documentation of treatment or prophylaxis is required.
REQUIRED
Hepatitis B surface antigen and hepatitis C screening
→ Required before biologic initiation. Positive hepatitis B requires specialist evaluation before Tremfya can be approved — disclose and address proactively if positive.
RECOMMENDED
Confirm whether Tremfya is processed under medical benefit or pharmacy benefit for this plan
→ Biologics administered by injection may be processed under either the medical benefit (buy-and-bill) or the pharmacy benefit (OptumRx — UHC specialty pharmacy) depending on the plan. The PA pathway is different for each. Confirm with UHC before submitting.
RECOMMENDED
| Criterion | Documentation Provided | Status |
|---|
| FDA-approved indication — moderate-to-severe plaque psoriasis | L40.0 confirmed; BSA 15%, PASI 18 | ✓ MET |
| BSA ≥10% or PASI ≥12 — moderate-to-severe threshold | BSA 15%, PASI 18 — both exceed threshold | ✓ MET |
| DLQI documented | Not yet documented in office note | ✗ GAP — administer and document before submission |
| Conventional systemic agent 1 — methotrexate failure | Hepatotoxicity documented — requires lab evidence | ⚠PARTIAL — attach LFT lab report |
| Conventional systemic agent 2 — apremilast failure | Inadequate response — requires sequential BSA/PASI measurements | ⚠PARTIAL — attach sequential measurements |
| TNF inhibitor step [VERIFY WITH UHC PLAN] | Not documented — plan-specific requirement unknown | ✗ VERIFY — call UHC before submitting |
| TB screening — negative result | Not yet confirmed in submission | ✗ GAP — required before biologic approval |
| Hepatitis B/C screening | Not yet confirmed in submission | ⚠PARTIAL — obtain and attach results |
| Prescriber specialty — dermatology | Board-certified dermatologist | ✓ MET |
| Benefit pathway confirmed (medical vs. pharmacy) | Not yet verified | ⚠VERIFY — determines PA submission pathway |
AAD-NPF Guidelines — Biologics for Psoriasis (2019, Updated)
The American Academy of Dermatology and National Psoriasis Foundation joint guidelines support IL-23 inhibitor use (including guselkumab) for moderate-to-severe plaque psoriasis in patients who have failed or are intolerant of conventional systemic therapies. Guselkumab is categorized as a high-efficacy biologic with a favorable safety profile. The guidelines support its use without mandatory TNF inhibitor step therapy when conventional agents have failed.
VOYAGE 1 and VOYAGE 2 Trials — Guselkumab Clinical Evidence
Phase 3 trials demonstrated guselkumab achieved PASI 90 response in approximately 73% of patients at week 16, with sustained responses through 48 weeks. In VOYAGE 2, guselkumab was superior to adalimumab (Humira) at week 24 — a finding that supports guselkumab as an appropriate biologic choice without mandatory prior TNF inhibitor exposure. Cite trial data directly in the LMN when arguing against mandatory TNF inhibitor step.
ERISA Status Advisory
If this is a self-funded ERISA plan, state insurance law step therapy override rights may not apply. Federal ERISA claims and appeals procedures govern. Confirm plan funding type before citing state-law step therapy protections in a formal appeal.
| Medication Requested | Guselkumab (Tremfya) 100mg subcutaneous injection |
| Dosing Schedule | 100mg at weeks 0 and 4, then every 8 weeks (maintenance) |
| HCPCS / J-Code | J0224 (verify current J-code with UHC at time of submission) |
| Diagnosis (ICD-10) | L40.0 — Psoriasis vulgaris (plaque psoriasis) |
| Payer | UnitedHealthcare |
| Benefit Pathway | [VERIFY — medical benefit (buy-and-bill) or pharmacy benefit (OptumRx — UHC specialty pharmacy)] |
| Requesting Specialty | Dermatology — board certified |
| Drug Class | IL-23 Inhibitor (anti-p19 monoclonal antibody) |
| Urgency | Routine |
| Submitting Provider NPI | [REQUIRED] |
| Patient Member ID | [REQUIRED] |
DECISION LOGIC IDENTIFIED
UHC's biologic step therapy for psoriasis follows a formulary tier framework. The criteria engine evaluates: (1) disease severity threshold, (2) conventional systemic failure documentation, (3) pre-biologic safety screening, and (4) plan-specific formulary tier requirements.
The single highest-risk unknown in this submission is whether UHC's specific plan for this patient requires a TNF inhibitor trial (adalimumab/Humira or etanercept) before an IL-23 inhibitor. UHC's clinical policies for biologics vary significantly by plan:
â–¸ Some UHC plans: conventional systemic failure (methotrexate + one other) is sufficient to approve any biologic
â–¸ Other UHC plans: require a TNF inhibitor trial (adalimumab preferred, as it is biosimilar-accessible) before IL-23 or IL-17 inhibitors
This distinction is not visible in the denial letter — it is a formulary tier requirement. The only way to know in advance is to call UHC Provider Services and ask directly. This call should happen before the PA is submitted, not after the denial.
The DLQI gap and missing lab documentation are secondary but addressable — close them before submission regardless of the TNF inhibitor question.
MISSING INFORMATION OR CRITERIA
▸ TNF inhibitor step — Unknown whether required. This is the highest-risk variable. Call UHC before submitting. If required and not addressed, the denial is automatic regardless of how strong the rest of the documentation is.
▸ DLQI score — Not documented in office note. Administer and score before submission. DLQI ≥10 (very large effect on quality of life) strengthens the medical necessity argument and is increasingly required by UHC.
▸ LFT lab report for methotrexate hepatotoxicity — The adverse effect is stated in the narrative but the lab evidence must be attached. Without a dated lab report showing elevated LFTs, the methotrexate failure is undocumented.
▸ Sequential BSA/PASI for apremilast — Start and end measurements must both be documented. A narrative statement that "apremilast was inadequate" without objective measurements does not satisfy UHC's criteria engine.
▸ TB screening result — Required before any biologic approval. If not on file or older than 12 months, obtain and attach before submission.
▸ Benefit pathway — Determine whether Tremfya will be administered under the medical benefit (office injection, buy-and-bill) or the pharmacy benefit (OptumRx specialty pharmacy). The PA submission pathway and form are different for each. Submitting through the wrong pathway is a common avoidable delay.
MOST LIKELY SUCCESSFUL NEXT STEP
Call UHC Provider Services before submitting the PA and ask: "Does your current clinical policy bulletin for guselkumab (Tremfya) for plaque psoriasis require a TNF inhibitor trial before an IL-23 inhibitor for this patient's plan?" Document the rep name and call date.
If TNF inhibitor is NOT required: close the remaining documentation gaps (DLQI, LFT lab, sequential BSA/PASI, TB screening) and submit the complete package.
If TNF inhibitor IS required: add a physician attestation letter explaining why TNF inhibitor step should be waived — citing the VOYAGE 2 trial data showing guselkumab superiority to adalimumab, the patient's hepatotoxicity history on methotrexate (which may create additional safety considerations with certain TNF inhibitors), and the AAD-NPF guidelines supporting IL-23 inhibitor use without mandatory TNF inhibitor step.
OPTION 1 · If TNF Inhibitor Required — Clinical Exception Argument
If UHC requires a TNF inhibitor step, prepare a clinical exception letter citing: (1) VOYAGE 2 trial data demonstrating guselkumab superiority to adalimumab — the most common TNF inhibitor required — making a TNF inhibitor trial a step backward from the evidence-based preferred agent; (2) the patient's prior hepatotoxicity on methotrexate creates additional liver safety considerations that may be relevant when selecting a TNF inhibitor; (3) AAD-NPF guidelines do not mandate TNF inhibitor step therapy before IL-23 inhibitors.
OPTION 2 · Janssen CarePath Patient Assistance
Janssen (manufacturer of Tremfya) offers the CarePath Savings Program, which can provide significant cost reduction for commercially insured patients while the PA or appeal is pending. For eligible patients, the program may reduce out-of-pocket costs to $0 per injection. The dermatologist's office can initiate enrollment. Do not delay treatment if the patient can access the medication through manufacturer support while the authorization process proceeds.
OPTION 3 · Peer-to-Peer with UHC Dermatology Medical Director
If the initial PA is denied, request a peer-to-peer call specifically with a UHC medical director who has dermatology expertise. General internal medicine reviewers may not be familiar with psoriasis severity scoring or the clinical rationale for IL-23 inhibitor selection over TNF inhibitors. Request a specialty-matched reviewer by name of specialty when scheduling the P2P call.
Level 1 — Verify TNF Step, Close Documentation Gaps, Submit
Call UHC first. Close all documentation gaps. Submit complete package. UHC's biologic PA response is typically 3–5 business days for routine requests.
Level 2 — Peer-to-Peer + Level 1 Appeal
If denied: request P2P with dermatology-matched reviewer and file Level 1 appeal simultaneously with supplemental documentation. Use VOYAGE 2 trial data and AAD-NPF guidelines as the clinical authority for the appeal letter.
Level 3 — External IMR (Florida)
If Level 1 appeal is denied: file for Independent Medical Review through the Florida Department of Insurance (fully insured commercial plans). Biologic denials for moderate-to-severe psoriasis with documented conventional systemic failure overturn at a meaningful rate at the IMR level when the clinical documentation is complete.
Level 4 — Janssen Medical Affairs
For complex biologic PA denials, Janssen's medical affairs team can provide clinical support, including providing clinical evidence packages and supporting documentation to assist with the appeal. Contact the Janssen medical science liaison for the region.
This case is navigable — but the TNF inhibitor step question must be answered before submission. Everything else is documentation that can be closed.
The clinical profile is strong: BSA 15%, PASI 18, two documented systemic failures across different mechanisms, a board-certified dermatologist prescribing. The VOYAGE 2 data gives the physician a clinical argument against mandatory TNF inhibitor step therapy that is grounded in the evidence and is not easy for UHC to dismiss.
Call UHC first. Know what you're submitting against. Close the documentation gaps. The dermatologist has the clinical record — PRISM has mapped the path.
Call UHC Provider Services — verify whether TNF inhibitor step is required for this specific plan before submitting
Confirm whether Tremfya processes under medical benefit or pharmacy benefit — determines PA submission pathway
Administer and document DLQI score in next office note — target ≥10 to establish quality of life impact
Attach dated LFT lab report showing elevation during methotrexate trial — objective evidence of hepatotoxicity required
Attach sequential BSA or PASI measurements from apremilast start and end — less than 25% improvement must be objectively documented
Obtain and attach negative TB screening result — required before any biologic approval
Obtain and attach hepatitis B/C screening results
If TNF inhibitor step required — prepare clinical exception letter citing VOYAGE 2 trial data and AAD-NPF guidelines
Submit complete package via UHC provider portal — retain confirmation and tracking number
Enroll patient in Janssen CarePath Savings Program while PA is pending — reduces out-of-pocket costs during authorization process
